American Society of Hematology

How I Treat Myeloproliferative Neoplasms

The following "How I Treat" sessions on myeloproliferative neoplasms (MPNs) took place at the 2018 ASH Meeting on Hematologic Malignancies. View the full schedule and program.

How I Treat CML When Initial TKI Therapy Has Not Been Successful

Gabriela Hobbs, MD, Massachusetts General Hospital

back to top

How I Treat Patients With Myelofibrosis Who Fail Front-Line Therapy

Ronald Hoffman, MD, Mt. Sinai School of Medicine

back to top

How I Treat Patients With "Problematic" Cases of Polycythemia Vera or Essential Thrombocythemia

Using a case-based approach, Dr. Ruben Mesa will discuss how he treats problematic cases of patients with the myeloproliferative neoplasms of essential thrombocythemia and polycythemia vera. He will focus specifically on what makes cases challenging, what options are available for individuals who have recurrent thrombotic events and for patients who fail more than one cytoreductive drug, how to address progression toward myelofibrosis, and situations such as pregnancy and surgical management.

Ruben Mesa, MD, Mays Cancer Center at UT Health San Antonio

Ruben A_  Mesa

Ruben A. Mesa, MD, is director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center. He is a physician investigator with a career focus on developing new therapies for patients with myeloproliferative neoplasms and seeking to better quantify the symptom burden these patients face, and as well as improving their quality of life. Dr. Mesa has been a lead investigator or co-lead investigator in more than 60 clinical trials throughout his career. He is a co-lead investigator of the clinical trial arm of the National Cancer Institute funded MPD Research Consortium and is an inaugural panel chair for the NCCN Guideline Panel on myeloproliferative neoplasms.

back to top